Clinical trial · Observational
18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients
18F-PSMA PET/CT Versus CT Alone in Initial Staging, Assessment of Therapy Response and Evaluation of Biochemical Recurrence in Prostatic Cancer Patients
NCT07485881CI-TRIAL-00106090not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the diagnostic performance of 18-F PSMA PET/CT and CT alone in initial staging, assessment of therapy response, as well as evaluation of biochemical recurrence of prostatic cancer patients The main question it aims to answer is: Does 18-F PSMA PET/CT have a superior role over CT in evaluation of prostatic cancer patients?
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
| Prostate Cancer Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Comparing 18-F PSMA PET/CT and CT in evaluation of prostatic cancer patients
- timeFrame
- 2 years
- description
- Comparison of diagnostic performance of 18-F PSMA PET/CT and CT in staging, assessment of therapy response and evaluation of biochemical recurrence
Secondary outcomes (1)
- measure
- Correlation between quantitative measures and other clinical, pathological and laboratory measures
- timeFrame
- 2 years
- description
- Correlation between quantitative measures and tumor burden of 18-F PSMA PET/CT with clinical, pathological and laboratory data including serum PSA, and Gleason Score
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: Patients with known prostate cancer referred for 18-F PSMA PET/CT study Exclusion Criteria: * Patients with claustrophobia * Patients refuse to do the scan
References
Publications (4)
- BACKGROUNDKratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA Cancer J Clin. 2025 Nov-Dec;75(6):485-497. doi: 10.3322/caac.70028. Epub 2025 Sep 2. PMID 40892160
- BACKGROUNDMazzone E, Cannoletta D, Quarta L, Chen DC, Thomson A, Barletta F, Stabile A, Moon D, Eapen R, Lawrentschuk N, Montorsi F, Siva S, Hofman MS, Chiti A, Murphy DG, Briganti A, Perera ML. A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment. Eur Urol. 2025 Jun;87(6):654-671. doi: 10.1016/j.eururo.2025.03.003. Epub 2025 Mar 27. PMID 40155242
- BACKGROUNDHadaschik B, Herrmann K. Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Eur Urol. 2020 Sep;78(3):470-471. doi: 10.1016/j.eururo.2020.04.051. Epub 2020 May 1. No abstract available. PMID 32370910
- BACKGROUNDMorawitz J, Kirchner J, Lakes J, Bruckmann NM, Mamlins E, Hiester A, Aissa J, Loberg C, Schimmoller L, Arsov C, Antke C, Albers P, Antoch G, Sawicki LM. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications. Eur J Radiol. 2021 Mar;136:109556. doi: 10.1016/j.ejrad.2021.109556. Epub 2021 Jan 16. PMID 33485127